PAND Gains 133.36%
PAND (PAND:NASDAQ) soared at $59.81, a gain of 133.4%. On Wed 24 Feb 21, PAND:NASDAQ touched a New 2-Week High of $25.63. The stock got featured on our News Catalysts scanner on Thu 25 Feb 21 at 02:44 PM in the 'ACQUISITION' category. From Wed 10 Feb 21, the stock recorded 66.67% Up Days and 60.00% Green Days
The share price of the company has been moving sideways in recent weeks.
About PAND (PAND:NASDAQ)
Pandion Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics designed to address the unmet needs of patients suffering from autoimmune diseases. Its pipeline products are PT101, PT627, PT001, and others. The firm has combined a network-based conceptualization of the immune system in advanced protein engineering to develop TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform.
Top 10 Gainers:
- PAND (PAND:NASDAQ), 133.36%
- ChromaDex Corporation (CDXC:NASDAQ), 92.4%
- TDH Holdings, Inc. (PETZ:NASDAQ), 34.73%
- ASLAN Pharmaceuticals Limited (ASLN:NASDAQ), 26.7%
- Dynatronics Corporation (DYNT:NASDAQ), 25%
- Workhorse Group Inc. (WKHS:NASDAQ), 24.72%
- Sunesis Pharmaceuticals, Inc. (SNSS:NASDAQ), 24.3%
- GameStop Corp. (GME:NYSE), 18.56%
- Brookdale Senior Living Inc. (BKD:NYSE), 18.53%
- TIRX (TIRX:NASDAQ), 17.11%